| Ident. | Authors (with country if any) | Title |
|---|
| 000030 (2017) |
Vincent Meininger [France] ; Angela Genge [Canada] ; Leonard H. Van Den Berg [Pays-Bas] ; Wim Robberecht [Belgique] ; Albert Ludolph [Allemagne] ; Adriano Chio [Italie] ; Seung H. Kim [Corée du Sud] ; P Nigel Leigh [Royaume-Uni] ; Matthew C. Kiernan [Australie] ; Jeremy M. Shefner [États-Unis] ; Claude Desnuelle [France] ; Karen E. Morrison [Royaume-Uni] ; Susanne Petri [Allemagne] ; Diane Boswell [Royaume-Uni] ; Jane Temple [Royaume-Uni] ; Rajat Mohindra [Royaume-Uni] ; Matt Davies [Royaume-Uni] ; Jonathan Bullman [Royaume-Uni] ; Paul Rees [Royaume-Uni] ; Arseniy Lavrov [Royaume-Uni] | Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. |
| 000232 (2016) |
Panying Rong [États-Unis] ; Yana Yunusova [Canada] ; Jun Wang [États-Unis] ; Lorne Zinman [Canada] ; Gary L. Pattee [États-Unis] ; James D. Berry [États-Unis] ; Bridget Perry [États-Unis] ; Jordan R. Green [États-Unis] | Predicting Speech Intelligibility Decline in Amyotrophic Lateral Sclerosis Based on the Deterioration of Individual Speech Subsystems |
| 000423 (2016) |
Eiichiro Nagata [Japon] ; Mieko Ogino [Japon] ; Kounosuke Iwamoto [Japon] ; Yasuhisa Kitagawa [Japon] ; Yasuo Iwasaki [Japon] ; Fumihito Yoshii [Japon] ; Joh-E. Ikeda [Japon, Canada] | Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients |
| 000589 (2015) |
Hiroshi Mitsumoto ; Peter L. Nagy ; Chris Gennings ; Jennifer Murphy ; Howard Andrews ; Raymond Goetz ; Mary Kay Floeter ; Jonathan Hupf ; Jessica Singleton ; Richard J. Barohn ; Sharon Nations ; Christen Shoesmith ; Edward Kasarskis ; Pam Factor-Litvak | Phenotypic and molecular analyses of primary lateral sclerosis |
| 000733 (2015) |
Celina H. Shirazipour ; Colin P. T. Baillie ; Karla Galaviz ; Jocelyn W. Jarvis ; Amy E. Latimer-Cheung | Evaluating the Theoretical Content of Online Physical Activity Information for People with Multiple Sclerosis |
| 000741 (2015) |
Sanjana Shellikeri [Canada] ; Yana Yunusova [Canada] ; Jordan R. Green [États-Unis] ; Gary L. Pattee [États-Unis] ; James D. Berry [États-Unis] ; Seward B. Rutkove [États-Unis] ; Lorne Zinman [Canada] | Electrical Impedance Myography (EIM) in the Evaluation of the Tongue Musculature in Amyotrophic Lateral Sclerosis (ALS) |
| 000822 (2015) |
Eugenia Fragalà [Italie] ; Giorgio Ivan Russo [Italie] ; Alessandro Di Rosa [Italie] ; Raimondo Giardina [Italie] ; Salvatore Privitera [Italie] ; Vincenzo Favilla [Italie] ; Francesco Patti [Italie] ; Blayne Welk [Canada] ; Sebastiano Cimino [Italie] ; Tommaso Castelli [Italie] ; Giuseppe Morgia [Italie] | Association Between the Neurogenic Bladder Symptom Score and Urodynamic Examination in Multiple Sclerosis Patients With Lower Urinary Tract Dysfunction |
| 000841 (2015) |
John C. Steele ; Robert Wresch [États-Unis] ; Samuel D. Hanlon [États-Unis] ; Jay Keystone [Canada] ; Yoav Ben-Shlomo [Royaume-Uni] | A unique retinal epitheliopathy is associated with amyotrophic lateral sclerosis/Parkinsonism-Dementia complex of Guam. |
| 000B80 (2014) |
Alexandro Gianforcaro [Canada] ; Mazen J. Hamadeh [Canada] | Vitamin D as a Potential Therapy in Amyotrophic Lateral Sclerosis |
| 000E51 (2013) |
Jay P. Ross [Canada] ; Cecily Q. Bernales [Canada] ; Joshua D. Lee [Canada] ; A Dessa Sadovnick [Canada] ; Anthony L. Traboulsee [Canada] ; Carles Vilari O-Güell [Canada] | Analysis of CYP27B1 in multiple sclerosis |
| 000F23 (2013) |
Serena Lattante [France] ; Guy A. Rouleau [Canada] ; Edor Kabashi [France, Canada] | TARDBP and FUS Mutations Associated with Amyotrophic Lateral Sclerosis: Summary and Update |
| 001889 (2011) |
Sheng Chen [Canada] ; Philip Seeman [Canada] ; Fang Liu [Canada] | Antipsychotic drug binding in the substantia nigra: An examination of high metoclopramide binding in the brains of normal, Alzheimer's disease, Huntington's disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia |
| 001914 (2011) |
Amit Bar-Or [Canada] ; Peter Rieckmann [Canada] ; Anthony Traboulsee [Canada] ; V. Wee Yong [Canada] | Targeting Progressive Neuroaxonal Injury: Lessons from Multiple Sclerosis |
| 001977 (2010) |
R. A. Marrie ; R. Rudick ; R. Horwitz ; G. Cutter ; T. Tyry ; D. Campagnolo ; T. Vollmer | Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis |
| 001F56 (2009) |
K. Poder [Canada] ; K. Ghatavi [Canada] ; Jd Fisk [Canada] ; Tl Campbell [Canada] ; S. Kisely [Australie] ; I. Sarty [Canada] ; K. Stadnyk [Canada] ; V. Bhan [Canada] | Social anxiety in a multiple sclerosis clinic population |
| 002042 (2009) |
Andrew Eisen [Canada] | Amyotrophic lateral sclerosis—Evolutionary and other perspectives |
| 002140 (2008) |
Ruth Ann Marrie [Canada] ; Gary Cutter [États-Unis] ; Tuula Tyry [États-Unis] ; Denise Campagnolo [États-Unis] ; Timothy Vollmer [États-Unis] | Smoking Status over Two Years in Patients with Multiple Sclerosis |
| 002199 (2008) |
Judith Miklossy [Canada] ; John C. Steele ; Sheng Yu ; Sherman Mccall ; Glenn Sandberg ; Edith G. Mcgeer ; Patrick L. Mcgeer | Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). |
| 002543 (2007) |
Edor Kabashi [Canada] ; Paul N. Valdmanis [Canada] ; Patrick Dion [Canada] ; Guy A. Rouleau [Canada] | Oxidized/misfolded superoxide dismutase‐1: the cause of all amyotrophic lateral sclerosis? |
| 002597 (2007) |
Carolyn Jack [Canada] ; Jack Antel [Canada] ; Wolfgang Brück [Allemagne] ; Tanja Kuhlmann [Allemagne] | Contrasting potential of nitric oxide and peroxynitrite to mediate oligodendrocyte injury in multiple sclerosis |
| 002658 (2007) |
Nikolaos Yiannakoulias [Canada] ; Donald P. Schopflocher [Canada] ; Sharon A. Warren [Canada] ; Lawrence W. Svenson [Canada] | Parkinson's disease, multiple sclerosis and changes of residence in Alberta |
